Alcon-STAAR deal clears HSR waiting period
Ticker: STAA · Form: DEFA14A · Filed: Sep 30, 2025 · CIK: 718937
| Field | Detail |
|---|---|
| Company | Staar Surgical Co (STAA) |
| Form Type | DEFA14A |
| Filed Date | Sep 30, 2025 |
| Risk Level | medium |
| Pages | 6 |
| Reading Time | 8 min |
| Key Dollar Amounts | $28, $1.5 billion |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, regulatory-approval, merger
TL;DR
Alcon's STAAR Surgical buy just got a green light from regulators, deal closing soon.
AI Summary
On September 30, 2025, Alcon and STAAR Surgical Company announced the expiration of the waiting period under the HSR Act for Alcon's proposed acquisition of STAAR Surgical. This is a significant step towards the completion of the transaction, which was initially announced on April 17, 2024.
Why It Matters
The expiration of the HSR Act waiting period means regulatory approval is progressing for Alcon's acquisition of STAAR Surgical, moving the deal closer to completion and potentially impacting the ophthalmic surgical device market.
Risk Assessment
Risk Level: medium — While regulatory approval is a positive step, the transaction is still subject to other closing conditions and potential market shifts.
Key Players & Entities
- Alcon (company) — Acquiring company
- STAAR Surgical Company (company) — Target company
- HSR Act (legal_act) — Regulatory approval requirement
- September 30, 2025 (date) — Date of announcement
- April 17, 2024 (date) — Date of initial deal announcement
FAQ
What is the significance of the HSR Act waiting period expiration?
The expiration of the waiting period under the HSR Act signifies that the U.S. antitrust authorities have completed their initial review of Alcon's proposed acquisition of STAAR Surgical and have not raised objections, allowing the transaction to proceed to the next stages.
When was the acquisition of STAAR Surgical by Alcon initially announced?
The acquisition was initially announced on April 17, 2024.
What is the filing type for this document?
This document is a Definitive Additional Materials filing (DEFA14A).
What is the primary business of STAAR Surgical Company?
STAAR Surgical Company is in the business of ophthalmic goods, specifically within the SIC code 3851.
What is the next major step after the HSR Act waiting period expiration for this deal?
Following the expiration of the HSR Act waiting period, the transaction is expected to move towards completion, subject to other customary closing conditions.
Filing Stats: 1,909 words · 8 min read · ~6 pages · Grade level 14.2 · Accepted 2025-09-30 08:48:23
Key Financial Figures
- $28 — anding shares of STAAR common stock for $28 per share in cash, which represents app
- $1.5 billion — s a total equity value of approximately $1.5 billion. "We are pleased to reach this milest
Filing Documents
- d11821ddefa14a.htm (DEFA14A) — 28KB
- g11821g36f93.jpg (GRAPHIC) — 23KB
- 0001193125-25-224160.txt ( ) — 61KB
Forward-looking Statements
Forward-looking Statements The information covered by this communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements often contain words such as "anticipate," "believe," "expect," "plan," "estimate," "project," "continue," "will," "should," "may," and similar terms. All statements in this communication that are not performance or achievements to be materially different from what is expressed or implied by the forward-looking statements, including, but not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the Alcon merger agreement or could cause the consummation of the proposed transaction to be delayed or to fail to occur; (2) the failure to obtain approval of the proposed transaction from STAAR's stockholders; (3) the failure to obtain certain required regulatory approvals or the failure to satisfy any of the other closing conditions to the completion of the proposed transaction within the expected timeframes or at all; (4) risks related to disruption of management's attention from ongoing business operations due to the proposed transaction; (5) the effect of the announcement of the proposed 3 transaction on the ability of STAAR to retain and hire key personnel and maintain relationships with its customers, suppliers and others with whom it does business, or on its operating results and business generally; (6) the ability of STAAR to meet expectations regarding the timing and completion of the transaction; (7) the outcome of any legal proceedings that may be instituted against STAAR related to the proposed transaction; (8) the possibility that STAAR's stock pric